SEC Tracker
Get the app

FibroBiologics FBLG

FibroBiologics Q1 FY25: net loss $5.0M; diluted EPS −$2.80

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers FibroBiologics reported for Q1 FY25, the quarter ended Mar 31, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$5.0MAgainst −$8.5M in Q1 FY2410-Q income statement, on EDGAR
  2. Diluted EPS−$2.80Against −$5.40 in Q1 FY24. Split-adjusted, as the tables show it; the filing reported −$0.1410-Q income statement, on EDGAR
  3. Cash and cash equivalents$8.7M+6% from $8.2M in Q1 FY2410-Q balance sheet, on EDGAR
  4. Cash from operations−$5.3MAgainst −$4.3M in Q1 FY2410-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when FibroBiologics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. Dare Bioscience DARE public float $21M, Jun 30, 2025
  2. Imunon IMNN public float $21M, Jun 30, 2025
  3. Fibrogen FGEN public float $21M, Jun 30, 2025
  4. Lisata Therapeutics LSTA public float $24M, Jun 30, 2025
  5. Nanoviricides NNVC public float $24M, Dec 31, 2025